Onco360...has been selected as a participating pharmacy by Bristol-Myers Squibb for ZENBEXUS (iberdomide), indicated, in combination with daratumumab and hyaluronidase-fihj and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least 1 prior line of therapy including a proteasome inhibitor and an immunomodulatory agent (GlobeNewswire) Sep 21, 2026
Commercial • Multiple Myeloma
|